The evolving use of biomarkers in heart transplantation: Consensus of an expert panel.
The evolving use of biomarkers in heart transplantation: Consensus of an expert panel.
复制标题
DOI：
10.1016/j.ajt.2023.02.025
复制
发表时间：
2023-06-01
期刊：
影响因子：
--
通讯作者：
Peyster, Eliot
中科院分区：
文献类型：
--
作者：
Kobashigawa, Jon;Hall, Shelley;Peyster, Eliot
在心脏移植中，使用生物标志物来检测排斥风险一直在发展。在这种情况下，什么是检测排斥反应和评估同种免疫反应状态的最可靠的测试或组合测试变得越来越不清楚。因此，在心脏和肾脏移植方面组织了一个虚拟专家小组，以评估新出现的诊断方法以及如何最好地利用它们来监测和管理移植患者。这份手稿涵盖了会议的核心内容，是美国移植学会胸部和重症监护社区实践的工作成果。本文回顾了目前可用的和新兴的诊断分析，并定义了心脏移植中未满足的生物标志物需求。会议与会者之间深入讨论的要点导致了协商一致声明的形成。本次会议应作为一个平台，进一步在心脏移植界就将生物标志物纳入管理方案的最佳框架达成共识，并改善生物标志物的开发、验证和临床应用。最终，这些生物标志物和新的诊断方法将改善移植患者的预后和优化生活质量。
In heart transplantation, the use of biomarkers to detect the risk of rejection has been evolving. In this setting, it is becoming less clear as to what is the most reliable test or combination of tests to detect rejection and assess the state of the alloimmune response. Therefore, a virtual expert panel was organized in heart and kidney transplantation to evaluate emerging diagnostics and how they may be best utilized to monitor and manage transplant patients. This manuscript covers the heart content of the conference and is a work product of the American Society of Transplantation's Thoracic and Critical Care Community of Practice. This paper reviews currently available and emerging diagnostic assays and defines the unmet needs for biomarkers in heart transplantation. Highlights of the in-depth discussions among conference participants that led to development of consensus statements are included. This conference should serve as a platform to further build consensus within the heart transplant community regarding the optimal framework to implement biomarkers into management protocols and to improve biomarker development, validation and clinical utility. Ultimately, these biomarkers and novel diagnostics should improve outcomes and optimize quality of life for our transplant patients.